Prediabetes and cardiovascular risk factors: the effectiveness of a guided self-determination counselling approach in primary health care, a randomized controlled trial DOI Creative Commons
Elín Arnardóttir, Árún K. Sigurðardóttir, Timothy Skinner

и другие.

BMC Public Health, Год журнала: 2024, Номер 24(1)

Опубликована: Ноя. 1, 2024

Identify individuals who are at risk of Type 2 diabetes, also a greater developing cardiovascular disease is important. The rapid worldwide increase in diabetes prevalence call for Primary Health Care to find feasible prevention strategies, reduce patient factors and promote lifestyle changes. Aim this randomized controlled trial was investigate how nurse-lead Guided Self-Determination counselling approach can assist people type lower their coronary heart risk.

Язык: Английский

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial DOI Creative Commons
Kenneth W. Mahaffey, Katherine R. Tuttle,

Mustafa Arici

и другие.

European Heart Journal, Год журнала: 2024, Номер unknown

Опубликована: Авг. 30, 2024

In the FLOW trial, semaglutide reduced risks of kidney and cardiovascular (CV) outcomes death in participants with type 2 diabetes mellitus (T2D) chronic disease (CKD). These prespecified analyses assessed effects on CV by CKD severity.

Язык: Английский

Процитировано

8
Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity DOI Creative Commons
Daniil Lisik, Ding Zou

Current Pulmonology Reports, Год журнала: 2025, Номер 14(1)

Опубликована: Янв. 11, 2025

Abstract Purpose of Review Pharmacologic alternatives in management obstructive sleep apnea (OSA) have been pursued for decades. Considering rapid development and promising findings recent years, we provide an overview novel agents treatment targets, ongoing trials, as well future perspectives. Recent Findings Several drugs demonstrate efficacy, though none is sufficient to cure the disease a monotherapy. Instead, main potential lies applying drug therapy specific subgroups or addition established treatments (e.g., positive airway pressure, oral appliance therapy). Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists may be particularly beneficial obese OSA patients. As major breakthrough, terzipatide, GIP analog GLP-1 agonist, has become first FDA-approved EMA-sanctioned pharmacologic option individuals. Beyond this, alerting could help manage residual daytime sleepiness improve functioning. However, long-term studies on safety, adherence, effectiveness are scarce highlight certain limitations challenges. Summary Incorporating pharmaceuticals along conventional synergy benefit patients, but side-effects risk reduction related adverse outcomes over time yet assessed. Furthermore, guidelines/frameworks mapping out applicable targets needed.

Язык: Английский

Процитировано

1
Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review DOI
P Schmidt, Eric Pasqualotto, Henrique Vilar dos Santos

и другие.

Obesity Research & Clinical Practice, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

1
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review DOI
Qingui Chen, Rayna J.S. Anijs,

Judith P.L. Verlaan

и другие.

Seminars in Thrombosis and Hemostasis, Год журнала: 2025, Номер unknown

Опубликована: Март 28, 2025

Novel antidiabetic drugs, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have significantly transformed the management landscape for type diabetes mellitus, cardiovascular diseases, chronic kidney owing to their well-established cardiorenal protective effects. Given shared risk factors comorbidities, it is relevant consider potential of venous thromboembolism (VTE) in individuals prescribed these novel medications. This literature review aims summarize currently available evidence on VTE associated with including GLP-1 dipeptidyl-peptidase IV (DPP-4) inhibitors, SGLT2 inhibitors. Following a comprehensive search PubMed using keywords backward reference searching, we identified 25 publications that directly reported associations between medications risk. Findings from studies, seven meta-analyses, reveal inconsistent results: some studies suggest agonists or DPP-4 may be increased VTE, whereas do not appear even factor. A notable limitation existing significant challenge posed by confounding observational while randomized controlled trials (RCTs) often concluded limited number events, if was studied. Furthermore, all focused primary leaving an important knowledge gap regarding whether drugs influence efficacy safety anticoagulants used preventing recurrence. Addressing gaps presents avenue future research.

Язык: Английский

Процитировано

1
Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials DOI Creative Commons
Yue Yin,

Minghan Zhang,

Qiuyu Cao

и другие.

Journal of Diabetes, Год журнала: 2025, Номер 17(4)

Опубликована: Апрель 1, 2025

ABSTRACT Background The cardioprotective effects of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)‐based therapies in nondiabetic individuals with overweight or obesity remain underexplored. This meta‐analysis evaluates their impact on cardiovascular events and metabolic parameters this population. Methods A was conducted using PubMed, Embase, Cochrane, Web Science databases from inception to June 18, 2024. Eligible studies were randomized controlled trials (RCTs) enrolling adults obesity. These compared GLP‐1RA‐based placebo reported parameters. Results total 29 RCTs involving 9 drugs 37 348 eligible participants included. Compared placebo, significantly reduced the risk (relative risk: 0.81, 95% confidence interval [CI]: [0.76, 0.87]), major adverse (0.80, [0.72, 0.89]), myocardial infarction (0.72, [0.61, 0.85]), all‐cause mortality (0.81, [0.71, 0.93]). No significant differences observed death stroke. Additionally, associated reductions some cardiometabolic Among therapies, orfroglipron demonstrated strong benefits reducing systolic blood pressure (mean difference: −7.10 mmHg, CI: [−11.00, −2.70]). Tirzepatide induced greatest reduction body mass index (−6.50 kg/m 2 , [−7.90, −5.10]) hemoglobin A1c concentrations (−0.39%, [−0.52, −0.26]). Retatrutide semaglutide most effective improving lipid profiles C‐reactive protein levels (−1.20 mg/dL, [−1.80, −0.63]), respectively. Conclusions In obesity, reduce improve findings underscore potential for individualized targeting factors.

Язык: Английский

Процитировано

1
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review DOI Creative Commons
Mohammed Sallam, Johan Snygg, Sara El Ghandour

и другие.

Obesities, Год журнала: 2025, Номер 5(2), С. 26 - 26

Опубликована: Апрель 18, 2025

Obesity represents a global health challenge, with critical and urgent need for long-term, sustainable management strategies. Tirzepatide is novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist. At first approved the treatment of type 2 diabetes mellitus, tirzepatide one latest clinically commercially available pharmacological options obesity management. This narrative review aimed to synthesize existing clinical evidence on efficacy safety in non-diabetic obese individuals. A comprehensive literature search was conducted using PubMed, Scopus, Web Science, ClinicalTrials.gov, Google Scholar databases identify relevant trials, meta-analyses, original studies assessing weight-loss impact from 2022 onwards. Synthesized indicated that achieved up 20.9% weight loss over 72 weeks (SURMOUNT-1), 18.4% after lifestyle intervention (SURMOUNT-3), 17.5% Chinese adults (SURMOUNT-CN), 25.3% continued 88 (SURMOUNT-4). Meta-analyses confirmed higher odds ≥5–20% versus semaglutide liraglutide, significantly reducing body mass index, waist circumference, blood pressure, atherosclerotic cardiovascular disease risk. Health-related quality life improved greater loss, gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild moderate, <5% discontinuation. significant cardiometabolic benefits, individuals, further research needed long-term efficacy, safety, application.

Язык: Английский

Процитировано

0
Venous thrombosis and obesity: from clinical needs to therapeutic challenges DOI Creative Commons
Federica La Rosa, Fabrizio Montecucco, Luca Liberale

и другие.

Internal and Emergency Medicine, Год журнала: 2024, Номер unknown

Опубликована: Сен. 13, 2024

Abstract Weight bias and stigma have limited the awareness of systemic consequences related to obesity. As narrative evolves, obesity is emerging as a driver enhancer many pathological conditions. Among these, risk venous thromboembolism (VTE) critical concern linked obesity, ranking third most common cardiovascular condition. Obesity recognized multifactorial factor for VTE, influenced by genetic, demographic, behavioral, socio-economic Despite established links, exact incidence VTE in general population remains largely unknown. The complexity distinguishing between provoked unprovoked coupled with gaps definition assessment still complicates tailored risk. reactivity, hypercoagulability, endothelial dysfunction are driven so-called ‘adiposopathy’. This state chronic inflammation metabolic disturbance amplifies thrombin generation alters function, promoting pro-thrombotic environment. Additionally, inflammation-induced clot formation—also referred ‘immunothrombosis’ further exacerbates people living Furthermore, current evidence highlights significant management particularly concerning prophylaxis treatment efficacy anticoagulants review underscores need therapeutic approaches well-designed clinical trials address unique challenges posed prevention management. Advanced research innovative strategies imperative improve outcomes reduce burden

Язык: Английский

Процитировано

2
Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists DOI
Teresa Vezza, Víctor M. Víctor

American Journal of Cardiovascular Drugs, Год журнала: 2024, Номер 24(4), С. 505 - 507

Опубликована: Май 15, 2024

Язык: Английский

Процитировано

0
Navigating the Evolving Roles of GLP-1 Agonists Safely and Effectively DOI Creative Commons
Kyle Ockerman, Heather Furnas, Amy Sheer

и другие.

Aesthetic Surgery Journal, Год журнала: 2024, Номер 44(11), С. 1241 - 1245

Опубликована: Июль 23, 2024

Язык: Английский

Процитировано

0
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients DOI Open Access
Vincenzo Quagliariello,

Maria Laura Canale,

Irma Bisceglia

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(20), С. 11299 - 11299

Опубликована: Окт. 21, 2024

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated beneficial effects, atherosclerosis failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits systemic anti-inflammatory effects in patients type-2 diabetes through the activation cAMP PI3K/AkT pathways inhibition NLRP-3 MyD88. In this narrative review, we highlight biochemical properties a deep analysis clinical preclinical evidence primary prevention cardiomyopathies. The overall picture review encourages study as potential strategy against atherosclerosis.

Язык: Английский

Процитировано

0